Radiation Therapy Oncology Group clinical trials with misonidazole

Journal Article · Fri May 15 00:00:00 EDT 1981 · Cancer; (United States)

DOI:https://doi.org/10.1002/1097-0142(19810515)47:10<2382::AID-CNCR2820471010>3.0.CO;2-F· OSTI ID:6389528

Wasserman, T H ^[1]; Stetz, J; Phillips, T L

---

1. Washington Univ., St. Louis, MO

This paper presents a review of the progressive clinical trials of the hypoxic cell radiosensitizer, misonidazole, in the Radiation Therapy Oncology Group (RTOG). Presentation is made of all the schemas of the recently completed and currently active RTOG Phase II and Phase III studies. Detailed information is provided on the clinical toxicity of the Phase II trials, specifically regarding neurotoxicity. With limitations in drug total dose, a variety of dose schedules have proven to be tolerable, with a moderate incidence of nausea and vomiting and mild peripheral neuropathy or central neuropathy. No other organ toxicity has been seen, specifically no liver, renal or bone marrow toxicities. An additional Phase III malignant glioma trial in the Brain Tumor Study Group is described.

• OSTI ID: 6389528
• Journal Information: Cancer; (United States), Vol. 47:10
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
62 RADIOLOGY AND NUCLEAR MEDICINE
MISONIDAZOLE
RADIOSENSITIVITY EFFECTS
TOXICITY
DOSE-RESPONSE RELATIONSHIPS
NAUSEA
NERVOUS SYSTEM DISEASES
RADIOTHERAPY
VOMITING
X RADIATION
ANTINEOPLASTIC DRUGS
AZOLES
DISEASES
DRUGS
ELECTROMAGNETIC RADIATION
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
IONIZING RADIATIONS
MEDICINE
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
RADIATIONS
RADIOLOGY
RADIOSENSITIZERS
SYMPTOMS
THERAPY
560151* - Radiation Effects on Animals- Man
550603 - Medicine- External Radiation in Therapy- (1980-)